The coordinated buying by three major passive managers suggests growing institutional confidence in KURA, potentially signaling improved sentiment ahead of clinical data or regulatory catalysts. Traders should monitor for follow-on buying and any upcoming company announcements.
KURA drugs
KURA drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 2 $8.68entry
- T+1 · 9mo ago −2.07%α −1.16% · $8.50
- T+5 · 8mo ago +8.18%α +9.39% · $9.39
- T+20 · 8mo ago −10.94%α −3.01% · $7.73
- T+60 · 6mo ago +19.93%α +10.60% · $10.41
How similar events traded
Executive Summary
Three major passive institutions, Morgan Stanley, Wells Fargo, and UBS, significantly increased their positions in Kura Oncology (KURA) during Q4 2024, collectively adding $5.0M in net new value. Despite one position showing a minor valuation decrease, the overall cluster reflects strong accumulation by large financial institutions.
Key Financial Metrics
Institutional Positions
Net institutional flow: $5.0M
▲ Buyers (3)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Morgan Stanley | DOUBLED | +171.3% | $28.5M | $4.9M |
| UBS | DOUBLED | +143% | $2.7M | $211.0K |
| Wells Fargo | ADD | +48.5% | $305.0K | -$155.6K |
Key Facts
- Morgan Stanley doubled its stake, adding 2.07M shares (171.3% increase), increasing value by $4.9M to $28.5M
- UBS doubled its position with a 143% share increase (185.7K shares added), boosting value by $211K to $2.7M
- Wells Fargo added 11.4K shares (48.5% increase), though the current value decreased slightly to $305K
- No institutional selling was detected in this quarter
Financial Impact
3 institutions accumulated $5.0M in net new positions during Q4 2024
Risk Factors
- All buyers are passive institutions, which may reflect index rebalancing rather than active conviction
- Wells Fargo's position decreased in value despite share increase, suggesting possible downward price pressure
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-KURA-2024-Q4 |
Track record
29 reports on KURA
5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +52.28% at T+60 after the Jun 3, 2026 report. 9 of 13 went positive at some point.
Filters
- Nov 16, 2026today Insider Buy Bullish 5/10 Entry $7.15 settles Feb 16
- Nov 16, 2026today 144 Neutral 3/10 Entry $7.15 settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.15 settles Feb 16
- Nov 10, 20266d ago S-3ASR Neutral 4/10 Entry $7.73 settles Feb 9
- Nov 10, 20266d ago Press Release Neutral 5/10 Entry $7.73 settles Feb 9
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $7.61 settles Feb 2
- Sep 29, 20266w ago Insider Cluster Bearish 5/10 Entry $10.71 settles Dec 24
- Sep 29, 20266w ago Press Release Bullish 6/10 Entry $10.81 settles Dec 23
- Sep 9, 20269w ago 8-K Bullish 6/10 Entry $12.09 settles Dec 3
- Sep 8, 20269w ago 8-K Neutral 2/10 Entry $12.52 settles Dec 2
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers